Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial Comparing the Efficacy and Safety of DA-3803(Recombinant Human Chorionic Gonadotrophin) and Ovidrel for Inducting Final Follicular Maturation and Early Luteinization in Women Undergoing Ovulation

NCT01718119 is registered in ClinicalTrials.gov with Dong-A Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01718119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01718119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial Comparing the Efficacy and Safety of DA-3803(Recombinant Human Chorionic Gonadotrophin) and Ovidrel for Inducting Final Follicular Maturation and Early Luteinization in Women Undergoing Ovulation
Lead sponsor
Dong-A Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2012
Completion date
Not reported
Enrollment
180 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hyperovulation induction for assisted reproduction treatment